Home›Articles›What the ZUPREME-1 trial reported for petrelintideArticleWhat the ZUPREME-1 trial reported for petrelintideArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnPetrelintide, Drugs and Medicinal Substances Well-attested SourcesRoche media release, 5 March 2026, petrelintide Phase II ZUPREME-1Headline summaryQuote, Headline summaryPetrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityView the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.